Asset profile
Amivantamab
Multispecific antibody
Evidence outlook
Accelerated approval: Non-Small Cell Lung Cancer (label: locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations)
Accelerated approval is granted on surrogate endpoints; confirmatory clinical benefit is being verified in ongoing trials. Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Weak signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
68 competitors in this universe: 8 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Amivantamab: this drug | Approved | Multispecific antibody | EGFR x c-MET | ||
| Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj) | Approved | Multispecific antibody | EGFR x c-MET | ||
| ALK202 | Phase 2 | Small molecule | EGFR x c-MET | ||
| EMB-01 | Phase 2 | Multispecific antibody | EGFR x c-MET | ||
| MCLA-129 | Phase 2 | Multispecific antibody | EGFR x c-MET | ||
| SKB571 For | Phase 2 | Antibody–drug conjugate | EGFR x c-MET | ||
| 225Ac-FPI-2068 | Phase 1 | Radiopharmaceutical | EGFR x c-MET | ||
| AZD9592 | Phase 1 | Antibody–drug conjugate | EGFR x c-MET | ||
| QLS5316 | Phase 1 | Small molecule | EGFR x c-MET | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor |
…and 53 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
2 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(31 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (4)
November 2026 (1)
What to watch
December 2026 (3)
What to watch
What to watch
What to watch
2027 (14)
January 2027 (1)
What to watch
February 2027 (1)
What to watch
April 2027 (2)
May 2027 (3)
What to watch
What to watch
What to watch
July 2027 (2)
What to watch
What to watch
August 2027 (1)
What to watch
October 2027 (2)
2028 (7)
March 2028 (1)
What to watch
May 2028 (2)
June 2028 (1)
What to watch
October 2028 (1)
What to watch
November 2028 (1)
What to watch
December 2028 (1)
What to watch
2029 (4)
February 2029 (1)
What to watch
May 2029 (1)
What to watch
June 2029 (1)
What to watch
August 2029 (1)
What to watch
2031 (1)
January 2031 (1)
What to watch
2032 (1)
December 2032 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.